Drug Trial Radar · NCT02026063
Telotristat Etiprate - Expanded Treatment for Patients With Carcinoid Syndrome Symptoms
Last checked: Nov 20, 2026Latest source record: Sep 17, 2019 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
124
Actual
Start
Jan 14, 2014
Primary completion
Sep 12, 2018
Study completion Sep 12, 2018
Sponsor
- Lead sponsor
- Lexicon PharmaceuticalsIndustry
- Sponsor type
- Industry
- First posted
- Jan 1, 2014
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Non randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Treatment
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The primary objective of this study is to evaluate the long-term safety and tolerability of orally administered telotristat etiprate.
Conditions
- Carcinoid Syndrome
Interventions
Telotristat etiprateDrug
Telotristat etiprate tablet (250 mg)
Primary outcomes
What the sponsor says the trial is designed to measure.
- Number of Participants With Treatment-Emergent Adverse Events (TEAEs)Time frame: First dose of study drug (Day 1) up to 15 days post last dose (approximately up to 236 weeks)
Locations
43 sites in 12 countries. Site status is shown where the registry gives one.
Lexicon Investigational Site
Mobile, Alabama
Lexicon Investigational Site
Stanford, California
Lexicon Investigational Site
Iowa City, Iowa
Lexicon Investigational Site
Lexington, Kentucky
Lexicon Investigational Site
Boston, Massachusetts
Lexicon Investigational Site
New York, New York
Lexicon Investigational Site
Philadelphia, Pennsylvania
Lexicon Investigational Site
St Leonards, New South Wales, Australia
Lexicon Investigational Site
Herston, Queensland, Australia
Lexicon Investigational Site
East Melbourne, Victoria, Australia
Lexicon Investigational Site
Edegem, Belgium
Lexicon Investigational Site
Ghent, Belgium
Lexicon Investigational Site
Yvoir, Belgium
Lexicon Investgational Site
Calgary, Alberta, Canada
Lexicon Investigational Site
Halifax, Nova Scotia, Canada
Lexicon Investigational Site
Lille, France
Lexicon Investigational Site
Lyon, France
Lexicon Investigational Site
Villejuif, France
Lexicon Investigational Site
Bad Berka, Germany
Lexicon Investigational Site
Berlin, Germany
Lexicon Investigational Site
Essen, Germany
Lexicon Investigational Site
Hamburg, Germany
Lexicon Investigational Site
Marburg, Germany
Lexicon Investigational Site
Jerusalem, Israel
Lexicon Investigational Site
Milan, Italy
Lexicon Investigational Site
Milan, Italy
Lexicon Investigational Site
Pisa, Italy
Lexicon Investigational Site
Torino, Italy
Lexicon Investigational Site
Amsterdam, Netherlands
Lexicon Investigational Site
Noord Holland, Netherlands
Lexicon Investigational Site
Noord-Brahant, Netherlands
Lexicon Investigational Site
Barcelona, Spain
Lexicon Investigational Site
Madrid, Spain
Lexicon Investigational Site
Seville, Spain
Lexicon Investigational Site
Lund, Sweden
Lexicon Investigational Site
Uppsala, Sweden
Lexicon Investigational Site
Coventry, United Kingdom
Lexicon Investigational Site
Glasgow, United Kingdom
Lexicon Investigational Site
London, United Kingdom
Lexicon Investigational Site
London, United Kingdom
Showing 40 of 43 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.